Case studies have reported benefit of BRAF/MEK inhibition in BRAF mutated colorectal NEC [27, 30], and a BRAF/EGFR-inhibitor combination is approved for BRAF mutated CRC, not limited to adenocarcinomas. This evidence concerns the gene EGFR and adenocarcinoma.